Correspondence 0001193125-24-275538 from Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc.
Date: Dec. 11, 2024 · CIK: 0001645460 · Accession: 0001193125-24-275538
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-38327
Referenced dates: December 5, 2024
Letter
December 11, 2024
By Electronic Submission
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549
Attention: Lynn Dicker and Eric Atallah
Re: Cue Biopharma, Inc.
Form 10-K for Fiscal Year Ended December 31, 2023
File No. 001-38327
Ladies and Gentlemen:
Cue Biopharma, Inc. (the “Company” or “we”) is responding to the comments of the staff (the “Staff”) of the Securities and Exchange Commission contained in the Staff’s letter dated December 5, 2024 (the “Comment Letter”), relating to the above referenced Form 10-K for the fiscal year ended December 31, 2023. For convenience, the heading and text of the Staff’s numbered comment from the Comment Letter is set forth below, followed by the Company’s response.
Form 10-K for Fiscal Year Ended December 31, 2023
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Research and Development, page 99
1. We note from the disclosures on page 5 that you have two oncology drug product candidates, CUE-101 and CUE-102. Please revise future filings to disclose the costs incurred during each period presented for each of your key research and development product candidates. If you do not track your research and development costs by project, disclose that fact and explain why you do not maintain and evaluate research and development costs by project. Also, revise to provide other quantitative and qualitative disclosures that give more transparency as to the type of research and development expenses incurred (i.e., by nature or type of expense) which should reconcile to total research and development expenses on your Statements of Operations.
Response: We respectfully acknowledge the Staff’s comments. We will include such information in our future filings.
Page 2
If you have any further questions or comments, or if you require any additional information, please contact the undersigned by telephone at (617) 949-2680. Thank you for your assistance.
Very truly yours,
/s/ Daniel R. Passeri
Show Raw Text
CORRESP 1 filename1.htm CORRESP December 11, 2024 By Electronic Submission Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attention: Lynn Dicker and Eric Atallah Re: Cue Biopharma, Inc. Form 10-K for Fiscal Year Ended December 31, 2023 File No. 001-38327 Ladies and Gentlemen: Cue Biopharma, Inc. (the “Company” or “we”) is responding to the comments of the staff (the “Staff”) of the Securities and Exchange Commission contained in the Staff’s letter dated December 5, 2024 (the “Comment Letter”), relating to the above referenced Form 10-K for the fiscal year ended December 31, 2023. For convenience, the heading and text of the Staff’s numbered comment from the Comment Letter is set forth below, followed by the Company’s response. Form 10-K for Fiscal Year Ended December 31, 2023 Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations Research and Development, page 99 1. We note from the disclosures on page 5 that you have two oncology drug product candidates, CUE-101 and CUE-102. Please revise future filings to disclose the costs incurred during each period presented for each of your key research and development product candidates. If you do not track your research and development costs by project, disclose that fact and explain why you do not maintain and evaluate research and development costs by project. Also, revise to provide other quantitative and qualitative disclosures that give more transparency as to the type of research and development expenses incurred (i.e., by nature or type of expense) which should reconcile to total research and development expenses on your Statements of Operations. Response: We respectfully acknowledge the Staff’s comments. We will include such information in our future filings. Page 2 If you have any further questions or comments, or if you require any additional information, please contact the undersigned by telephone at (617) 949-2680. Thank you for your assistance. Very truly yours, /s/ Daniel R. Passeri Daniel R. Passeri Chief Executive Officer ___________________ cc: Kerri-Ann Millar, Chief Financial Officer, Cue Biopharma, Inc. Cynthia Mazareas, Wilmer Cutler Pickering Hale and Dorr LLP